

Dicerna Pharmaceuticals Inc  
Form SC 13D/A  
November 02, 2018

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 6)\***

Dicerna Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

253031108

(CUSIP Number)

RA Capital Management, LLC

20 Park Plaza, Suite 1200

Boston, MA 02116

Telephone: 617.778.2512

Attn: Peter Kolchinsky

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 30, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 253031108

Names of Reporting Persons.

1

**RA Capital Management, LLC**

2

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ..

(b) ..

3

SEC Use Only

Source of Funds (See Instructions):

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

5

..

6

Citizenship or Place of Organization. **Massachusetts**

Number

7 Sole Voting Power **0**

of Shares

8 Shared Voting Power

Beneficially

**3,324,989**

Owned by

9 Sole Dispositive Power **0**

Each

Reporting

10 Shared Dispositive Power **3,324,989**

Person With

11 Aggregate Amount Beneficially Owned by Each Reporting Person

**3,324,989**

12 Check if the Aggregate  
Amount in Row (11)  
Excludes Certain Shares (See  
Instructions) ..  
Percent of Class Represented  
by Amount in Row (11)

13

**5.4%<sup>1</sup>**

Type of Reporting Person  
(See Instructions)

14

**IA, OO (Limited Liability  
Company)**

<sup>1</sup> Represents 3,324,989 shares of the common stock (the “Common Stock”) of Dicerna Pharmaceuticals, Inc. (the “Issuer”) which constitutes approximately 5.4% of the class outstanding. The percentage calculation assumes that there are currently 61,806,905 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Prospectus as filed with the Securities and Exchange Commission (“SEC”) on September 10, 2018.

CUSIP No. 253031108

Names of Reporting Persons.

1

**Peter Kolchinsky**

2

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ..

(b) ..

3

SEC Use Only  
Source of Funds (See Instructions):

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e):

5

..

6

Citizenship or Place of Organization. **United States**

Number

7 Sole Voting Power **0**

of Shares

8 Shared Voting

Beneficially

Power **3,324,989**

Owned by

9 Sole Dispositive Power **0**

Each

10 Shared Dispositive

Reporting

Power **3,324,989**

Person With

11

Aggregate Amount Beneficially Owned by Each Reporting Person

**3,324,989**

12 Check if the  
Aggregate Amount in  
Row (11) Excludes  
Certain Shares (See  
Instructions) ..  
Percent of Class  
Represented by  
Amount in Row (11)

13

**5.4%<sup>2</sup>**

14 Type of Reporting  
Person (See  
Instructions)

**HC, IN**

<sup>2</sup> Represents 3,324,989 shares of the common stock (the "Common Stock") of Dicerna Pharmaceuticals, Inc. (the "Issuer") which constitutes approximately 5.4% of the class outstanding. The percentage calculation assumes that there are currently 61,806,905 outstanding shares of the Common Stock of the Issuer, based on the Issuer's Prospectus as filed with the Securities and Exchange Commission ("SEC") on September 10, 2018.

CUSIP No. 253031108

Names of Reporting Persons.

1

**RA Capital Healthcare Fund, L.P.**

2

Check the Appropriate Box if a  
Member of a Group (See Instructions)

(a) ..

(b) ..

3

SEC Use Only

Source of Funds (See Instructions):

4

WC

Check if disclosure of legal  
proceedings is required pursuant to  
Items 2(d) or 2(e):

5

..

6

Citizenship or Place of  
Organization. **Delaware**

Number 7 Sole Voting

Power **0**

of Shares 8 Shared

Voting

Beneficially 9 Power **2,913,506**

Sole

Owned by Dispositive

Power **0**

Each

10 Shared

Reporting Dispositive

Power **2,913,506**

Person With

11 Aggregate Amount  
Beneficially Owned by  
Each Reporting Person

**2,913,506**

12 Check if the Aggregate  
Amount in Row (11)  
Excludes Certain Shares  
(See Instructions)   
Percent of Class  
Represented by Amount in  
Row (11)

13

**4.7%<sup>3</sup>**

14 Type of Reporting Person  
(See Instructions)

14

**PN (Limited Partnership)**

<sup>3</sup> Represents 2,913,506 shares of the common stock (the “Common Stock”) of Dicerna Pharmaceuticals, Inc. (the “Issuer”) which constitutes approximately 4.7% of the class outstanding. The percentage calculation assumes that there are currently 61,806,905 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Prospectus as filed with the Securities and Exchange Commission (“SEC”) on September 10, 2018.



**Explanatory Note**

This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on February 5, 2014, as amended to date (the "Statement") by (i) RA Capital Management, LLC (the "RA Capital"), (ii) Peter Kolchinsky and (iii) RA Capital Healthcare Fund, L.P. ("Fund" and together with each of the foregoing, the "Reporting Persons"), relating to the Common Stock (the "Common Stock") of Dicerna Pharmaceuticals, Inc. (the "Issuer"). Capitalized terms used herein without definition shall have the meaning set forth in the Statement.

**Item 5. Interest in Securities of the Issuer**

Item 5(a)-(b) of the Statement is hereby amended and restated in its entirety as follows:

(a)-(b) See Items 7-11 of the cover pages and Item 2 of this Statement.

Item 5(c) of the Statement is hereby amended and supplemented by adding the following:

(c) From the date of the most recent amendment to this Schedule 13D through November 1, 2018, the Reporting Persons disposed of 608,500 shares of Common Stock in a series of open market transactions on the Nasdaq Global Market. Details by date of the transactions are as follows:

<b>Transaction Date</b>	<b>No. Shares</b>	<b>Price</b>
Sell 30-Oct-2018	219,072* and 30,928	\$13.8603
Sell 31-Oct-2018	156,330* and 22,070	\$13.4619
Sell 1-Nov-2018	157,820* and 22,280	\$13.3757

Shares marked with an \* were acquired by the Fund. The remaining shares were acquired for the Account.

(d) None.

(e) As a result of the transactions described herein, the Fund no longer beneficially owns more than 5% of the outstanding Common Stock and therefore, upon the filing of this amendment, will no longer be a Reporting Person.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 1, 2018

RA CAPITAL MANAGEMENT, LLC

By: /s/ Rajeev Shah

-----

Rajeev Shah

Authorized Signatory

PETER KOLCHINSKY

/s/ Peter Kolchinsky

-----

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Management, LLC

Its: General Partner

By: /s/ Rajeev Shah

-----

Rajeev Shah

Authorized Signatory